Schedule III cannabis would open FDA pathways, not legalization

December 13, 2025

Trump-backed cannabis rescheduling to Schedule III could expand FDA-style trials for cannabinoid drugs and shift advantages toward pharma and larger firms.

Search

RECENT PRESS RELEASES

15 Really Good Gifts They’ll Never Guess You Bought Last-Minute (All Under $50!)

SWI Editorial Staff2025-12-13T11:03:53-08:00December 13, 2025|

Bitcoin creator Satoshi disappeared on this day 15 years ago, leaving a final public messa

SWI Editorial Staff2025-12-13T11:03:11-08:00December 13, 2025|

XRP expands to Ethereum and Solana: Key insights and impact

SWI Editorial Staff2025-12-13T11:01:51-08:00December 13, 2025|

EarthTalk – What is ‘sand mining’ and why is it bad for the environment?

SWI Editorial Staff2025-12-13T10:55:53-08:00December 13, 2025|

Overnight stays at Grand Canyon likely to resume soon

SWI Editorial Staff2025-12-13T10:55:26-08:00December 13, 2025|

Military-Led West African States Launch Regional Investment Bank

SWI Editorial Staff2025-12-13T10:54:51-08:00December 13, 2025|